Searched for
LANTUS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analysts- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analysts
- Stolen insulin warning: How a missing batch of India's widely prescribed drug could put diabetes patients at serious risk
- Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 cr from Indian pharma giantsSanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...15 Apr, 2025, 11.24 AM IST
- Sanofi plans to launch 1 or 2 products in India every yearSanofi prioritizes the Indian market, focusing on diabetes, consumer health, and innovation. With a strategic shift under Hrosz's leadershi...02 Apr, 2024, 12.46 AM IST
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...22 Jan, 2022, 04.07 PM IST
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...21 Oct, 2021, 10.30 AM IST
- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...30 Jul, 2021, 06.49 PM IST
- Sanofi's valuations are attractive: Why it is stock pick of weekSanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push...04 May, 2021, 09.52 AM IST
- Biocon Biologics launches Semglee, drug to control high blood sugar, in USTo encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...31 Aug, 2020, 05.11 PM IST
- Biocon gets US FDA nod to launch insulin glargineThe product branded as Semglee has an identical amino acid sequence to Sanofi’s Lantus® and is approved for the same indications. This is t...12 Jun, 2020, 09.54 AM IST
- Biocon's partner Mylan gets favourable ruling from US patent authority for 4 devices"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. Thi...01 Jun, 2020, 03.41 PM IST
- Mylan-Biocon’s insulin biosimilar faces FDA hurdleFirms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.02 Jun, 2018, 10.37 AM IST
- Regulatory actions won't stop growth of emerging markets, says Sanofi EVPEmerging markets account for 7% of Sanofi’s global revenues, driven by its limited product in rare diseases, diabetes and oncology segments.04 Dec, 2017, 02.15 PM IST
- European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.03 Nov, 2016, 08.48 PM IST
- Coming soon: Novo Nordisk’s long-lasting insulin injectionNovo is betting big on Tresiba in the emerging markets after it failed to get an approval for the drug from the US Food and Drug Administra...30 Aug, 2013, 11.52 AM IST
- Govt slashes drug pricesThe drug price regulator National Pharmaceutical Pricing Authority has revised prices of 887 medicines, including steroids, insulin, vitami...07 Aug, 2009, 12.19 AM IST
- Insulin prices may come down by 70 per centInsulin prices are likely to fall by up to 70 per cent as drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has bro...06 Aug, 2009, 09.26 PM IST
- Stocks to watch: Punj Lloyd, Godrej Consumer, HCL, ACC, JP Associates, Wockhardt, BioconNew York's main contract, light sweet crude for September delivery was at $71.43 per barrel, after surging $2.13 in previous session. Brent...04 Aug, 2009, 10.00 AM IST
- Wockhardt, Biocon insulin prices to fall by 70%Indian copycats of French drug maker Sanofi Aventis’ premium insulin formulation, Lantus, will soon become about 70% cheaper with the count...04 Aug, 2009, 02.59 AM IST
Load More
